L-NAC for reversal of opioid-induced respiratory depression

Status

Completed

Phases

Phase 3Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503912-34-00

Enrollment

Registered

2023-05-12

Start date

2023-07-19

Completion date

2024-09-09

Last updated

2024-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

none, healthy subjects only

Brief summary

Minute ventilation

Detailed description

End-tidal carbon dioxide partial pressure, Respiratory frequency, Tidal volume, Arterial blood gas analyses, Blood plasma concentrations of fentanyl and L-NAC

Interventions

DRUGFentanyl hameln 50 microgram/ml

DRUGoplossing voor injectie

DRUGFluimucil 200 mg/ml concentraat voor oplossing voor infusie

DRUG0.9% NaCl solution for infusion

DRUGNaloxone 400 micrograms/ml solution for injection/infusion

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Minute ventilation	—

Secondary

Measure	Time frame
End-tidal carbon dioxide partial pressure, Respiratory frequency, Tidal volume, Arterial blood gas analyses, Blood plasma concentrations of fentanyl and L-NAC	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026